CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,779 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01083121
NCT01083121N/ACompleted

Post-Marketing Surveillance of Humira Injection in Korean Patients Under the "New-Drug Re-examination"

AbbVie (prior sponsor, Abbott)·observational·Posted Mar 9, 2010·Updated Aug 21, 2013

In Brief

An observational study for Rheumatoid Arthritis and 4 related conditions. Completed, enrolled 1,779 participants across 77 sites.

Detailed Summary

Patients who take Humira as prescribed by physicians as per Korean label will be enrolled and observed in normal medical practice setting for not less than 3 months following first dose of Humira. Information on demographics, diagnosis and medical history, results of tuberculosis skin test, results of chest X-ray, Humira treatment information, concomitant medication, physician's global assessment for effectiveness, disease activity assessment for rheumatoid arthritis, disease activity assessment for Crohn's Disease, disease activity assessment for Psoriasis and adverse events will be recorded on case report forms.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesSouth Korea
CollaboratorsEisai Co., Ltd.

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 9, 2010
Enrollment StartApr 1, 2007
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 16.3 years ago